Access requires that you are 21 years of age or older. Products are for laboratory and research use only — not for human or veterinary use, consumption, or clinical application.
Access requires that you are 21 years of age or older. Products are for laboratory and research use only — not for human or veterinary use, consumption, or clinical application.
HCG reference material, supplied as a lyophilized powder in a sealed vial for in-vitro laboratory research and analytical method development. Each fill size is a separate SKU. Lot and COA records are shown when assigned.
This listing is a research chemical / reference material. No therapeutic, preventive, or diagnostic claims are made or implied. The storefront displays only approved analytical characterization data released through its public report records.
HCG is a glycoprotein hormone. An endogenous human glycoprotein hormone. It shares an alpha subunit with LH, FSH and TSH, but carries a unique beta subunit.
The beta subunit carries a 24-amino-acid C-terminal extension, which extends half-life to 24–36 hours against roughly 60 minutes for LH. That extension is the functional difference between them.
Binds the LH/choriogonadotropin receptor on Leydig cells in the testes and on theca and granulosa cells in the ovary. That activates Gαs, adenylyl cyclase, cAMP and protein kinase A, which in turn activates STARD1 — the rate-limiting cholesterol-transport step in steroidogenesis. Reported as roughly ten-fold more potent than LH at stimulating cAMP. Vectra makes no claim as to mechanism or effect.
FDA-approved pharmaceutical hCG products exist and are prescribed under their own labelling. Material sourced from research-chemical vendors is typically sold as research-use-only and is not the approved product.
A long-established pharmaceutical hormone with an FDA-approved label.
Studied in steroidogenesis and reproductive endocrinology. Vectra supplies it as a reference material for in-vitro laboratory research and analytical method development only.
Worth stating plainly because the opposite is widely marketed: the FDA label explicitly states that hCG has no effect on fat mobilisation, appetite, or body fat distribution. That directly refutes the weight-loss claims made for it.
hCG increases aromatisation. Literature on off-label use recommends monitoring oestradiol, total and free testosterone, LH and FSH, haematocrit, PSA, and semen parameters.
Our sources carry no CAS number, molecular formula, molecular weight, or stability data for HCG.
Approved pharmaceutical products containing this hormone exist. This material is supplied for in-vitro research use only. No therapeutic, preventive, or diagnostic claims are made or implied.
These are the specific, documented failure modes that lot-level third-party analysis addresses. A report reachable from the lot code printed on the vial — without asking the seller for it — is the only document that answers 'is this vial what the label says'. That is why every Vectra vial carries a QR code resolving to its own lot's published report.
Findings reported by commercial testing providers. Each names its source; none is registry- or peer-review-grade, so read them as a documented pattern rather than established prevalence.
Yes, and altered certificates have been reported in this market at material rates — see the testing findings above. Three properties make a report hard to fake:
Peptide identity data in the vendor market is often wrong in ways that are hard to see. Near-identical compounds get their CAS numbers, residue ranges, formulas and molecular weights swapped. A certificate can be internally consistent and still describe a different molecule than the label names. Most commercial peptide material ships as an acetate salt, not free base. The two forms have different measured masses, so a figure quoted against the wrong one will not reconcile. A report that does not state which form it assayed cannot be checked at all.
The standard our own reports are built to meet:
FDA has acted in this market between 2024 and 2026. Actions include a civil forfeiture over $1.7 million against a compounding operation, several rounds of warning letters to peptide vendors, and more than thirty letters in March 2026 concerning compounded GLP-1 products.
Buyers here increasingly compare document trail, not price.
HCG reference material, supplied as a lyophilized powder in a sealed vial for in-vitro laboratory research and analytical method development. Each fill size is a separate SKU. Lot and COA records are shown when assigned.
This listing is a research chemical / reference material. No therapeutic, preventive, or diagnostic claims are made or implied. The storefront displays only approved analytical characterization data released through its public report records.
HCG is a glycoprotein hormone. An endogenous human glycoprotein hormone. It shares an alpha subunit with LH, FSH and TSH, but carries a unique beta subunit.
The beta subunit carries a 24-amino-acid C-terminal extension, which extends half-life to 24–36 hours against roughly 60 minutes for LH. That extension is the functional difference between them.
Binds the LH/choriogonadotropin receptor on Leydig cells in the testes and on theca and granulosa cells in the ovary. That activates Gαs, adenylyl cyclase, cAMP and protein kinase A, which in turn activates STARD1 — the rate-limiting cholesterol-transport step in steroidogenesis. Reported as roughly ten-fold more potent than LH at stimulating cAMP. Vectra makes no claim as to mechanism or effect.
FDA-approved pharmaceutical hCG products exist and are prescribed under their own labelling. Material sourced from research-chemical vendors is typically sold as research-use-only and is not the approved product.
A long-established pharmaceutical hormone with an FDA-approved label.
Studied in steroidogenesis and reproductive endocrinology. Vectra supplies it as a reference material for in-vitro laboratory research and analytical method development only.
Worth stating plainly because the opposite is widely marketed: the FDA label explicitly states that hCG has no effect on fat mobilisation, appetite, or body fat distribution. That directly refutes the weight-loss claims made for it.
hCG increases aromatisation. Literature on off-label use recommends monitoring oestradiol, total and free testosterone, LH and FSH, haematocrit, PSA, and semen parameters.
Our sources carry no CAS number, molecular formula, molecular weight, or stability data for HCG.
Approved pharmaceutical products containing this hormone exist. This material is supplied for in-vitro research use only. No therapeutic, preventive, or diagnostic claims are made or implied.
These are the specific, documented failure modes that lot-level third-party analysis addresses. A report reachable from the lot code printed on the vial — without asking the seller for it — is the only document that answers 'is this vial what the label says'. That is why every Vectra vial carries a QR code resolving to its own lot's published report.
Findings reported by commercial testing providers. Each names its source; none is registry- or peer-review-grade, so read them as a documented pattern rather than established prevalence.
Yes, and altered certificates have been reported in this market at material rates — see the testing findings above. Three properties make a report hard to fake:
Peptide identity data in the vendor market is often wrong in ways that are hard to see. Near-identical compounds get their CAS numbers, residue ranges, formulas and molecular weights swapped. A certificate can be internally consistent and still describe a different molecule than the label names. Most commercial peptide material ships as an acetate salt, not free base. The two forms have different measured masses, so a figure quoted against the wrong one will not reconcile. A report that does not state which form it assayed cannot be checked at all.
The standard our own reports are built to meet:
FDA has acted in this market between 2024 and 2026. Actions include a civil forfeiture over $1.7 million against a compounding operation, several rounds of warning letters to peptide vendors, and more than thirty letters in March 2026 concerning compounded GLP-1 products.
Buyers here increasingly compare document trail, not price.